Alethio Therapeutics Raises €80.46M Series A for Blood Cancer Drugs
Oxford spin-out Alethio Therapeutics closed an oversubscribed €80.46M Series A led by Sofinnova Partners and RA Capital to advance antibody ATX-011 into the clinic.
Topic
Blood Cancer
Topic
Blood Cancer
Alethio Therapeutics Raises $90M Series A for Blood Cancer Drugs
Sofinnova Partners and RA Capital co-led a $90M Series A in Oxford spinout Alethio Therapeutics to move blood cancer drug ATX-011…